Jorge Vergas

817 total citations
17 papers, 178 citations indexed

About

Jorge Vergas is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Jorge Vergas has authored 17 papers receiving a total of 178 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Infectious Diseases, 7 papers in Virology and 6 papers in Epidemiology. Recurrent topics in Jorge Vergas's work include HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (6 papers) and HIV/AIDS Research and Interventions (6 papers). Jorge Vergas is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (6 papers) and HIV/AIDS Research and Interventions (6 papers). Jorge Vergas collaborates with scholars based in Spain. Jorge Vergas's co-authors include Vicente Estrada, Sergio Serrano‐Villar, A Fernández‐Cruz, Cristina Prieto, Noemí Cabello, Teresa Puerta, José M. Lagarón, Marı́a José Galindo, Adrián Valls Carbó and Rocı́o Martı́n and has published in prestigious journals such as PLoS ONE, Hepatology and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Jorge Vergas

12 papers receiving 177 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jorge Vergas Spain 6 78 68 58 56 38 17 178
Jude Armishaw Australia 5 60 0.8× 49 0.7× 88 1.5× 56 1.0× 31 0.8× 7 204
Eveline Verheij Netherlands 7 119 1.5× 65 1.0× 53 0.9× 120 2.1× 46 1.2× 10 245
Sebastiaan O Verboeket Netherlands 7 63 0.8× 26 0.4× 37 0.6× 80 1.4× 27 0.7× 10 112
Cal Cohen United States 8 219 2.8× 158 2.3× 34 0.6× 91 1.6× 11 0.3× 15 260
Chiara Montrucchio Italy 9 126 1.6× 63 0.9× 83 1.4× 41 0.7× 13 0.3× 14 211
Sara Lino Portugal 5 44 0.6× 32 0.5× 43 0.7× 35 0.6× 5 0.1× 14 98
Cecilia Kanyama Malawi 8 97 1.2× 29 0.4× 81 1.4× 52 0.9× 8 0.2× 18 179
Kevin O’Laughlin United States 7 27 0.3× 24 0.4× 29 0.5× 15 0.3× 45 1.2× 13 146
Luis Escosa Spain 7 26 0.3× 15 0.2× 41 0.7× 14 0.3× 7 0.2× 14 92
Laura Comi Italy 9 127 1.6× 91 1.3× 39 0.7× 32 0.6× 8 0.2× 29 180

Countries citing papers authored by Jorge Vergas

Since Specialization
Citations

This map shows the geographic impact of Jorge Vergas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jorge Vergas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jorge Vergas more than expected).

Fields of papers citing papers by Jorge Vergas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jorge Vergas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jorge Vergas. The network helps show where Jorge Vergas may publish in the future.

Co-authorship network of co-authors of Jorge Vergas

This figure shows the co-authorship network connecting the top 25 collaborators of Jorge Vergas. A scholar is included among the top collaborators of Jorge Vergas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jorge Vergas. Jorge Vergas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Cabello, Alfonso, Álvaro Mena, Miguel Torralba, et al.. (2025). Dolutegravir (DTG) + Lamivudine (3 TC) in Antiretroviral-Naive Adults With HIV With and Without Genotypic Resistance Testing Results: 96-Week Effectiveness and Tolerability of REDOLA Study. JAIDS Journal of Acquired Immune Deficiency Syndromes. 100(2). e4–e7.
2.
Valencia, Eulalia, Marta Montero, José Sanz, et al.. (2024). Prospective study for the early detection of lung carcinoma in patients with HIV infection (GESIDA study 8815). Enfermedades infecciosas y microbiologia clinica (English ed ). 43(3). 125–132.
3.
Valencia, Eulalia, Marta Montero, José Sanz, et al.. (2024). Estudio prospectivo para la detección precoz de carcinoma pulmonar en pacientes con infección por VIH (estudio GESIDA 8815). Enfermedades Infecciosas y Microbiología Clínica. 43(3). 125–132.
4.
Berenguer, Juan, Teresa Aldámiz‐Echevarría, Víctor Hontañón, et al.. (2024). Clinical outcomes and prognostic factors after HCV clearance with DAA in HIV/HCV-coinfected patients with advanced fibrosis/cirrhosis. Hepatology. 81(1). 238–253. 3 indexed citations
5.
Martı́n-Carbonero, Luz, Ángela Gutiérrez, Otilia Bisbal, et al.. (2023). Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid. Enfermedades Infecciosas y Microbiología Clínica.
6.
Martı́n-Carbonero, Luz, Ángela Gutiérrez, Otilia Bisbal, et al.. (2023). Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid. Enfermedades infecciosas y microbiologia clinica (English ed ). 42(8). 414–419.
7.
Brañas, Fátima, Miguel Torralba, Antonio Antela, et al.. (2023). Effects of frailty, geriatric syndromes, and comorbidity on mortality and quality of life in older adults with HIV. BMC Geriatrics. 23(1). 4–4. 19 indexed citations
8.
Hernáez, Bruno, Ana Muñoz‐Gómez, África Sanchiz, et al.. (2022). Monitoring monkeypox virus in saliva and air samples in Spain: a cross-sectional study. The Lancet Microbe. 4(1). e21–e28. 51 indexed citations
9.
Cabello, Alfonso, Luz Martı́n-Carbonero, Jesús Sanz, et al.. (2022). 48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort. PLoS ONE. 17(11). e0277606–e0277606. 10 indexed citations
10.
Brañas, Fátima, Miguel Torralba, Antonio Antela, et al.. (2022). Different profiles among older adults with HIV according to their chronological age and the year of HIV diagnosis: The FUNCFRAIL cohort study (GeSIDA 9817). PLoS ONE. 17(3). e0266191–e0266191. 13 indexed citations
11.
Casado, José L., Pilar Vizcarra, José Luís Blanco, et al.. (2020). Maintenance of virologic suppression and improvement in comorbidities after simplification to raltegravir plus boosted darunavir among treatment-experienced HIV-infected patients. International Journal of STD & AIDS. 31(5). 467–473. 3 indexed citations
12.
Pasquau, Juan, Carmen Hidalgo-Tenorio, Marisa Montes, et al.. (2018). High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial. PLoS ONE. 13(4). e0195068–e0195068. 30 indexed citations
13.
Bernardino, José Ignacio, Eulalia Valencia, V. Moreno, et al.. (2014). Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART‐experienced patients. Journal of the International AIDS Society. 17(4S3). 19787–19787. 4 indexed citations
14.
Santos, Ignacio de los, Eulalia Valencia, Víctor Asensi, et al.. (2013). Efficacy and Tolerability of Darunavir/Ritonavir in Combination with Abacavir/Lamivudine: An Option in Selected HIV-Infected Patients. HIV Clinical Trials. 14(5). 254–261. 2 indexed citations
15.
Pasquau, Juan, Carmen Hidalgo, Marisa Montes, et al.. (2012). A clinical trial to compare the quality of life of HIV+ patients who start monotherapy with LPV/r versus continuing triple therapy with a boosted PI. Journal of the International AIDS Society. 15(S4). 1–2. 1 indexed citations
16.
Estrada, Vicente, et al.. (2009). Smoking cessation in HIV patients: rate of success and associated factors. HIV Medicine. 10(10). 614–619. 41 indexed citations
17.
Moreno, Fernando, et al.. (2003). Fractura patológica de sacro en un paciente VIH en terapia antirretroviral de alta eficacia. Anales de Medicina Interna. 20(9). 496–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jude Armishaw Breakdown of academic impact, for papers by Eveline Verheij Breakdown of academic impact, for papers by Sebastiaan O Verboeket Breakdown of academic impact, for papers by Cal Cohen Breakdown of academic impact, for papers by Chiara Montrucchio Breakdown of academic impact, for papers by Sara Lino Breakdown of academic impact, for papers by Cecilia Kanyama Breakdown of academic impact, for papers by Kevin O’Laughlin Breakdown of academic impact, for papers by Luis Escosa Breakdown of academic impact, for papers by Laura Comi
Rankless by CCL
2026